Latest Sézary's disease Stories

2012-04-02 04:20:02

Tokyo, Apr 2, 2012 - (JCN Newswire) - Eisai Co., Ltd. and Minophagen Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning bexarotene (generic name), a treatment for cutaneous T-cell lymphoma (CTCL).Under the terms of the agreement, Eisai shall grant Minophagen Pharmaceutical the exclusive rights to develop and commercialize bexarotene in Asia, Oceania, the Middle East and Eastern Europe, amongst other regions. However, Eisai retains the right of...

2011-08-16 14:42:54

A three-pronged immunotherapy approach nearly doubles five-year survival among patients with rare leukemic form of cutaneous T-cell lymphoma, reports a new study by dermatologists from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania. In a retrospective study of 98 patients with advanced Sezary Syndrome "“ treated over a 25 year time span at the Hospital of the University of Pennsylvania "“ patients treated with combination therapy...

2010-09-07 06:30:00

PHILADELPHIA, Sept. 7 /PRNewswire/ -- TenX Biopharma, Inc. announced today that it has re-initiated enrollment in the pivotal Phase III clinical trial assessing zanolimumab treatment for cutaneous T-cell lymphoma (CTCL) patients (ClinicalTrials.gov identifier: NCT00127881). The trial enrollment was suspended in October 2008 while Genmab (CO:GEN) was seeking a out-license agreement to further develop the compound. TenX Biopharma acquired global rights to zanolimumab in February, 2010 from...

2010-01-05 20:30:00

Scott & White's Cancer Research Institute (CRI) has launched two clinical trials targeting cancers that affect both adults and children. "These studies may lead to eventual development of agents that we hope will improve quality and duration of life," said Arthur Frankel, M.D., director of the CRI, and director of Scott & White's Cancer Center and division of hematology/oncology. One of the studies aims to find the maximum safest dose of an agent for treatment of T-cell lymphomas and...

2008-06-17 09:00:08

Gloucester Pharmaceuticals today announced that positive data from a Phase 2 trial of romidepsin conducted by the U.S. National Cancer Institute (NCI) were presented at the 13th Congress of the European Hematology Association in Copenhagen, Denmark. Romidepsin is a novel, cyclic peptide, pan-HDAC inhibitor under investigation for hematologic malignancies. In a presentation entitled Romidepsin Induces Clinically Significant and Durable Responses in Relapsed or Refractory CTCL: A National...

Word of the Day
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.